Literature DB >> 23105118

The M2 module of the Cys-His-rich domain (CHRD) of PCSK9 protein is needed for the extracellular low-density lipoprotein receptor (LDLR) degradation pathway.

Yascara Grisel Luna Saavedra1, Robert Day, Nabil G Seidah.   

Abstract

PCSK9 enhances the cellular degradation of the LDL receptor (LDLR), leading to increased plasma LDL cholesterol. This multidomain protein contains a prosegment, a catalytic domain, a hinge region, and a cysteine-histidine rich domain (CHRD) composed of three tightly packed modules named M1, M2, and M3. The CHRD is required for the activity of PCSK9, but the mechanism behind this remains obscure. To define the contribution of each module to the function of PCSK9, we dissected the CHRD structure. Six PCSK9 deletants were generated by mutagenesis, corresponding to the deletion of only one (ΔM1, ΔM2, ΔM3) or two (ΔM12, ΔM13, ΔM23) modules. Transfection of HEK293 cells showed that all deletants were well processed and expressed compared with the parent PCSK9 but that only those lacking the M2 module were secreted. HepG2 cells lacking endogenous PCSK9 (HepG2/shPCSK9) were used for the functional analysis of the extracellular or intracellular activity of PCSK9 and its deletants. To analyze the ability of the deletants to enhance the LDLR degradation by the intracellular pathway, cellular expressions revealed that only the ΔM2 deletant retains a comparable total LDLR-degrading activity to full-length PCSK9. To probe the extracellular pathway, HepG2/shPCSK9 cells were incubated with conditioned media from transfected HEK293 or HepG2/shPCSK9 cells, and cell surface LDLR levels were analyzed by FACS. The results showed no activity of any secreted deletant compared with PCSK9. Thus, although M2 is dispensable for secretion, its presence is required for the extracellular activity of PCSK9 on cell surface LDLR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23105118      PMCID: PMC3527936          DOI: 10.1074/jbc.M112.394023

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

Authors:  Ingrid K Kotowski; Alexander Pertsemlidis; Amy Luke; Richard S Cooper; Gloria L Vega; Jonathan C Cohen; Helen H Hobbs
Journal:  Am J Hum Genet       Date:  2006-01-20       Impact factor: 11.025

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

3.  Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

Authors:  Shirya Rashid; David E Curtis; Rita Garuti; Norma N Anderson; Yuriy Bashmakov; Y K Ho; Robert E Hammer; Young-Ah Moon; Jay D Horton
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-01       Impact factor: 11.205

4.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

5.  Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein.

Authors:  Fen Du; Yvonne Hui; Michelle Zhang; MacRae F Linton; Sergio Fazio; Daping Fan
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

6.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

7.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

9.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation.

Authors:  Nabil G Seidah; Suzanne Benjannet; Louise Wickham; Jadwiga Marcinkiewicz; Stephanie Belanger Jasmin; Stefano Stifani; Ajoy Basak; Annik Prat; Michel Chretien
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

10.  Functional characterization of Narc 1, a novel proteinase related to proteinase K.

Authors:  Saule Naureckiene; Linh Ma; Kodangattil Sreekumar; Urmila Purandare; C Frederick Lo; Ying Huang; Lillian W Chiang; Jill M Grenier; Bradley A Ozenberger; J Steven Jacobsen; Jeffrey D Kennedy; Peter S DiStefano; Andrew Wood; Brendan Bingham
Journal:  Arch Biochem Biophys       Date:  2003-12-01       Impact factor: 4.013

View more
  22 in total

1.  The Proprotein Convertase Subtilisin/Kexin Type 9-resistant R410S Low Density Lipoprotein Receptor Mutation: A NOVEL MECHANISM CAUSING FAMILIAL HYPERCHOLESTEROLEMIA.

Authors:  Delia Susan-Resiga; Emmanuelle Girard; Robert Scott Kiss; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Zuhier Awan; Chutikarn Butkinaree; Alexandre Fleury; Armand Soldera; Yves L Dory; Alexis Baass; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-12-20       Impact factor: 5.157

2.  Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.

Authors:  Chutikarn Butkinaree; Maryssa Canuel; Rachid Essalmani; Steve Poirier; Suzanne Benjannet; Marie-Claude Asselin; Anna Roubtsova; Josée Hamelin; Jadwiga Marcinkiewicz; Ann Chamberland; Johann Guillemot; Gaétan Mayer; Sangram S Sisodia; Yves Jacob; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2015-06-17       Impact factor: 5.157

3.  Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9.

Authors:  Quoc-Tuan Le; Matthieu Blanchet; Nabil G Seidah; Patrick Labonté
Journal:  J Biol Chem       Date:  2015-07-20       Impact factor: 5.157

4.  An Unbiased Mass Spectrometry Approach Identifies Glypican-3 as an Interactor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR) in Hepatocellular Carcinoma Cells.

Authors:  Kévin Ly; Rachid Essalmani; Roxane Desjardins; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2016-10-07       Impact factor: 5.157

5.  Annexin A2 reduces PCSK9 protein levels via a translational mechanism and interacts with the M1 and M2 domains of PCSK9.

Authors:  Kévin Ly; Yascara Grisel Luna Saavedra; Maryssa Canuel; Sophie Routhier; Roxane Desjardins; Josée Hamelin; Janice Mayne; Claude Lazure; Nabil G Seidah; Robert Day
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

Review 6.  The multifaceted proprotein convertases: their unique, redundant, complementary, and opposite functions.

Authors:  Nabil G Seidah; Mohamad S Sadr; Michel Chrétien; Majambu Mbikay
Journal:  J Biol Chem       Date:  2013-06-17       Impact factor: 5.157

7.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Single Domain Antibodies Are Potent Inhibitors of Low Density Lipoprotein Receptor Degradation.

Authors:  Elodie Weider; Delia Susan-Resiga; Rachid Essalmani; Josée Hamelin; Marie-Claude Asselin; Surendra Nimesh; Yahya Ashraf; Keith L Wycoff; Jianbing Zhang; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2016-06-08       Impact factor: 5.157

8.  Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

Authors:  Rachel M DeVay; David L Shelton; Hong Liang
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

Review 9.  The Multifaceted Biology of PCSK9.

Authors:  Nabil G Seidah; Annik Prat
Journal:  Endocr Rev       Date:  2022-05-12       Impact factor: 25.261

10.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) can mediate degradation of the low density lipoprotein receptor-related protein 1 (LRP-1).

Authors:  Maryssa Canuel; Xiaowei Sun; Marie-Claude Asselin; Eustache Paramithiotis; Annik Prat; Nabil G Seidah
Journal:  PLoS One       Date:  2013-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.